Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis

Abstract Background Vibrational and chiroptical spectroscopy of blood plasma is an advanced experimental diagnostic approach that allows the identification of disease-specific molecular patterns. This study aimed to test its potential to distinguish between different stages of metabolic dysfunction-...

Full description

Saved in:

Bibliographic Details
Main Authors:	Barbora Nováková, Ondřej Vrtělka, Kateřina Králová, Lucie Habartová, Václav Šmíd, Karel Dvořák, Jaromír Petrtýl, Kateřina Žížalová, Jan Stříteský, Libor Vítek, Martin Leníček, Vladimír Setnička, Radan Brůha
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	Journal of Translational Medicine
Subjects:	Metabolic dysfunction-associated steatohepatitis (MASH) Metabolic dysfunction-associated steatotic liver disease (MASLD) Liver fibrosis Simple steatosis Fourier-transform infrared (FTIR) spectroscopy Raman spectroscopy
Online Access:	https://doi.org/10.1186/s12967-025-06885-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice
by: Kim B. Pedersen, et al.
Published: (2025-05-01)

Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study
by: Jie Chen, et al.
Published: (2025-04-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications
by: Bruno Ramos-Molina, et al.
Published: (2024-11-01)

Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-03-01)

Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis
by: Semiu O. Gbadamosi, et al.
Published: (2025-01-01)

Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis
by: Saranya C. Reghupaty, et al.
Published: (2025-08-01)

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
by: Vincent Wai-Sun Wong, et al.
Published: (2025-07-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
by: Shyam Patel, et al.
Published: (2025-01-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050
by: Jincheng Tang, et al.
Published: (2025-07-01)

The evolution of international definitions of fatty liver disease and insights into the working definition and features of the 2024 Chinese guideline
by: Li CHEN, et al.
Published: (2025-06-01)

Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
by: Ying Geng, et al.
Published: (2024-11-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease
by: Wenhao Wu, et al.
Published: (2025-07-01)

Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation
by: Wenxiu Liu, et al.
Published: (2025-05-01)

Comprehensive profiling of candidate biomarkers and immune infiltration landscape in metabolic dysfunction-associated steatohepatitis
by: Zhangliu Jin, et al.
Published: (2025-06-01)

Liver fibrosis progression analyzed with AI predicts renal decline
by: Dan-Qin Sun, et al.
Published: (2025-05-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

Deep learning-based method for grading histopathological liver fibrosis in rodent models of metabolic dysfunction-associated steatohepatitis
by: Soo Min Ko, et al.
Published: (2025-07-01)

Association of estimated glucose disposal rate with risk of future metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases: a prospective cohort study
by: Yan Li, et al.
Published: (2025-07-01)

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis
by: Farah Abdelhameed, et al.
Published: (2025-04-01)

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
by: Woo-Young Shin, et al.
Published: (2025-04-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yeo-Wool Kang, et al.
Published: (2024-11-01)

Risk Prediction in Patients With Metabolic Dysfunction–Associated Steatohepatitis Using Natural Language Processing
by: Jordan Guillot, et al.
Published: (2025-01-01)

Revisiting the causal impact of lipid traits on metabolic dysfunction‐associated fatty liver disease: Insights from a multidimensional plasma lipid profile
by: Fang Xie, et al.
Published: (2025-05-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)

Kidney Biopsy Findings in People With Metabolic Dysfunction–Associated Steatohepatitis
by: Evgeniya Pasternak, et al.
Published: (2025-05-01)

Association between periodontitis and mortality in participants with metabolic dysfunction-associated steatotic liver disease: results from NHANES
by: Zhaofu Zhang, et al.
Published: (2025-04-01)

Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
by: Francisco Aguirre, et al.
Published: (2025-07-01)

Alnustone Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease by Facilitating Mitochondrial Fatty Acid β‐Oxidation via Targeting Calmodulin
by: Shourui Hu, et al.
Published: (2025-08-01)

The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data
by: Haijun Ma, et al.
Published: (2025-01-01)

Low-carbohydrate diets reduce cardiovascular risk factor levels in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
by: Shanshan Pi, et al.
Published: (2025-08-01)

Comprehensive Analysis of Differentially Expressed Profiles of mRNA 5-Methylcytosine Modification in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yueying Yang, et al.
Published: (2025-04-01)

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
by: Pingping Jin, et al.
Published: (2025-07-01)

Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study
by: Jihan Sun, et al.
Published: (2025-05-01)

Augmenter of Liver Regeneration Crotonylation Assists in Mitochondria-ER Contact to Alleviate Hepatic SteatosisSummary
by: Xiao-lin Wang, et al.
Published: (2025-01-01)